Tianjin Zhong Xin Pharmaceutical Group Corporation Limited
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People's Republic of China. The company manufactures and sells of biochemical pharmaceutical products. It also engages in research and development of chinese patent medicines, chemical raw materials and… Read more
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) - Total Assets
Latest total assets as of June 2025: €12.85 Billion EUR
Based on the latest financial reports, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) holds total assets worth €12.85 Billion EUR as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Total Assets Trend (2013–2024)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's total assets of €12.85 Billion consist of 61.4% current assets and 38.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.3% |
| Accounts Receivable | €756.29 Million | 7.0% |
| Inventory | €1.29 Billion | 11.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €337.62 Million | 3.1% |
| Goodwill | €12.30 Million | 0.1% |
Asset Composition Trend (2013–2024)
This chart illustrates how Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's current assets represent 61.4% of total assets in 2024, an increase from 60.6% in 2013.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2024, up from 10.4% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2013.
- Asset Diversification: The largest asset category is inventory at 11.9% of total assets.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited Competitors by Total Assets
Key competitors of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Chongkundang
KO:001630
|
Korea | ₩1.60 Trillion |
|
Redwood Scientific Technologies Inc
PINK:RSCI
|
USA | $296.47K |
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
Discovery Gold Corp
PINK:GRNF
|
USA | $1.36 Million |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Icure Pharmaceutical Incorporation
KQ:175250
|
Korea | ₩128.95 Billion |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940
|
China | CN¥2.92 Billion |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Tianjin Zhong Xin Pharmaceutical Group Corporation Limited generates 0.68x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Tianjin Zhong Xin Pharmaceutical Group Corporation Limited generates $ 20.70 in net profit.
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.06 | 1.56 | 2.59 |
| Quick Ratio | 1.75 | 1.26 | 1.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.20 Billion | € 2.92 Billion | € 3.29 Billion |
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited - Advanced Valuation Insights
This section examines the relationship between Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.98 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | 5.3% |
| Total Assets | €10.77 Billion |
| Market Capitalization | $1.22 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Tianjin Zhong Xin Pharmaceutical Group Corporation Limited's assets grew by 5.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2013–2024)
The table below shows the annual total assets of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €10.77 Billion | +5.26% |
| 2023-12-31 | €10.23 Billion | +0.72% |
| 2022-12-31 | €10.16 Billion | +12.02% |
| 2021-12-31 | €9.07 Billion | +9.46% |
| 2020-12-31 | €8.28 Billion | +5.61% |
| 2019-12-31 | €7.84 Billion | +10.38% |
| 2018-12-31 | €7.11 Billion | +7.30% |
| 2017-12-31 | €6.62 Billion | +4.11% |
| 2016-12-31 | €6.36 Billion | +4.81% |
| 2015-12-31 | €6.07 Billion | +11.62% |
| 2014-12-31 | €5.44 Billion | +3.32% |
| 2013-12-31 | €5.26 Billion | -- |